181 related articles for article (PubMed ID: 32079019)
1. Molecular Profile of Gastrointestinal Stromal Tumors in Sixty-Eight Patients from a Single Swiss Institution.
Haefliger S; Marston K; Juskevicius D; Meyer-Schaller N; Forster A; Nicolet S; Komminoth P; Stauffer E; Cathomas G; Hoeller S; Tornillo L; Dirnhofer S; Terracciano LM; Bihl M; Matter MS
Pathobiology; 2020; 87(3):171-178. PubMed ID: 32079019
[TBL] [Abstract][Full Text] [Related]
2. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
5. Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
Bombac A; Zakotnik B; Bucic M; Setrajcic Dragos V; Gazic B; Stegel V; Klancar G; Novakovic S
Int J Oncol; 2020 Jun; 56(6):1468-1478. PubMed ID: 32236636
[TBL] [Abstract][Full Text] [Related]
6. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
7. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Ali Abuderman AW; M Aldakheel F
Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
[TBL] [Abstract][Full Text] [Related]
8. Correlation of treatment outcome in sanger/RT‑qPCR
Unk M; Bombač A; Jezeršek Novaković B; Stegel V; Šetrajčič Dragoš V; Blatnik O; Klančar G; Novaković S
Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35904169
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutations in KIT/PDGFRA positive gastrointestinal stromal tumours (GISTs): Is their frequency underestimated?
Jašek K; Váňová B; Grendár M; Štanclová A; Szépe P; Hornáková A; Holubeková V; Plank L; Lasabová Z
Pathol Res Pract; 2020 Nov; 216(11):153171. PubMed ID: 32836055
[TBL] [Abstract][Full Text] [Related]
10. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.
Jasek K; Buzalkova V; Minarik G; Stanclova A; Szepe P; Plank L; Lasabova Z
Virchows Arch; 2017 Jan; 470(1):29-36. PubMed ID: 27864688
[TBL] [Abstract][Full Text] [Related]
11. Mutational profile of KIT and PDGFRA genes in gastrointestinal stromal tumors in Peruvian samples.
Buleje J; Acosta Ó; Guevara-Fujita M; Enriquez Y; Taxa L; Machicado E; Lizaraso-Caparó F; Fujita R
Rev Esp Enferm Dig; 2015 Feb; 107(2):72-8. PubMed ID: 25659388
[TBL] [Abstract][Full Text] [Related]
12. Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA.
Mayr P; Märkl B; Agaimy A; Kriening B; Dintner S; Schenkirsch G; Schneider-Stock R
Langenbecks Arch Surg; 2019 Aug; 404(5):605-613. PubMed ID: 30877378
[TBL] [Abstract][Full Text] [Related]
13. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).
Daniels M; Lurkin I; Pauli R; Erbstösser E; Hildebrandt U; Hellwig K; Zschille U; Lüders P; Krüger G; Knolle J; Stengel B; Prall F; Hertel K; Lobeck H; Popp B; Theissig F; Wünsch P; Zwarthoff E; Agaimy A; Schneider-Stock R
Cancer Lett; 2011 Dec; 312(1):43-54. PubMed ID: 21906875
[TBL] [Abstract][Full Text] [Related]
15. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
[TBL] [Abstract][Full Text] [Related]
17. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study.
Rubió-Casadevall J; Borràs JL; Carmona-García MC; Ameijide A; Gonzalez-Vidal A; Ortiz MR; Bosch R; Riu F; Parada D; Martí E; Miró J; Sirvent JJ; Galceran J; Marcos-Gragera R
World J Surg Oncol; 2015 Feb; 13():47. PubMed ID: 25885906
[TBL] [Abstract][Full Text] [Related]
18. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
19. Molecular cytology genotyping of primary and metastatic GI stromal tumors by using a custom two-gene targeted next-generation sequencing panel with therapeutic intent.
Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
Gastrointest Endosc; 2016 Dec; 84(6):950-958.e3. PubMed ID: 27118626
[TBL] [Abstract][Full Text] [Related]
20. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
